Geriatric oncology: European Union regulatory perspectives and initiatives

J Geriatr Oncol. 2013 Apr;4(2):202-4. doi: 10.1016/j.jgo.2012.12.003. Epub 2013 Jan 9.

Abstract

The world population is gradually ageing. With cancer being prominently a disease of the elderly, availability of information for oncology drugs in this patient population is becoming critical for their safe and effective use. Drug regulatory thinking and recommendations towards obtaining this information continue to evolve over time accordingly in order to address this information gap.

MeSH terms

  • Aged
  • Antineoplastic Agents / pharmacokinetics*
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic*
  • Drug Approval / legislation & jurisprudence
  • Endpoint Determination
  • European Union
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / epidemiology
  • Patient Safety
  • Population Dynamics

Substances

  • Antineoplastic Agents